A detailed history of Nuveen Asset Management, LLC transactions in Altimmune, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 665,058 shares of ALT stock, worth $4.12 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
665,058
Previous 913,000 27.16%
Holding current value
$4.12 Million
Previous $9.29 Million 52.42%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

SELL
$5.91 - $10.23 $1.47 Million - $2.54 Million
-247,942 Reduced 27.16%
665,058 $4.42 Million
Q1 2024

May 13, 2024

SELL
$8.22 - $13.81 $6.69 Million - $11.2 Million
-814,316 Reduced 47.14%
913,000 $9.29 Million
Q4 2023

Feb 14, 2024

SELL
$2.14 - $11.62 $3.68 Million - $20 Million
-1,719,462 Reduced 49.89%
1,727,316 $19.4 Million
Q3 2023

Nov 14, 2023

SELL
$2.4 - $3.45 $29,210 - $41,989
-12,171 Reduced 0.35%
3,446,778 $8.96 Million
Q2 2023

Aug 14, 2023

BUY
$3.45 - $5.97 $658,563 - $1.14 Million
190,888 Added 5.84%
3,458,949 $12.2 Million
Q1 2023

May 15, 2023

BUY
$4.19 - $16.83 $8,790 - $35,309
2,098 Added 0.06%
3,268,061 $13.8 Million
Q4 2022

Feb 14, 2023

BUY
$8.74 - $16.45 $455,030 - $856,436
52,063 Added 1.62%
3,265,963 $53.7 Million
Q3 2022

Nov 14, 2022

BUY
$10.67 - $22.41 $1.6 Million - $3.35 Million
149,620 Added 4.88%
3,213,900 $41 Million
Q2 2022

Aug 15, 2022

SELL
$3.94 - $11.77 $712,840 - $2.13 Million
-180,924 Reduced 5.58%
3,064,280 $35.9 Million
Q1 2022

May 16, 2022

BUY
$5.9 - $9.45 $5.6 Million - $8.97 Million
949,372 Added 41.35%
3,245,204 $22.2 Million
Q4 2021

Feb 14, 2022

BUY
$8.69 - $12.48 $12.9 Million - $18.6 Million
1,490,012 Added 184.91%
2,295,832 $19.4 Million
Q3 2021

Nov 12, 2021

BUY
$8.43 - $16.81 $4.78 Million - $9.54 Million
567,253 Added 237.78%
805,820 $12.3 Million
Q2 2021

Aug 16, 2021

BUY
$9.85 - $16.46 $2.35 Million - $3.93 Million
238,567 New
238,567 $2.35 Million

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $304M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.